Home › NCT07798505

A First-in-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of HMB-003 in Healthy Volunteers

Who can join

Ages 18 to 50 · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Participant is aged 18 to 50 years, inclusive, at the time of signing informed consent.
* Overall healthy as determined by medical evaluation including physical examination, vital signs, laboratory tests, and ECG.

Exclusion Criteria:

* Participant has a history of clinically significant hypersensitivity to any excipients of the study drug
* Participant is pregnant, breastfeeding, or \<6 weeks postpartum.
* Participant has received investigational drug or device in another clinical study within 30 days or 5 half-lives, whichever is longer, before dosing.

About the study

The purposes of this clinical study are

1. To see how the new drug (HMB-003) under study is tolerated in healthy volunteers, and if there are any important side effects. 2. To measure the amount of HMB-003 in the body after injection.

What is being tested

• HMB-003 (drug)
• Placebo (drug)

Sponsor: Hemab ApS · Participants: 40 · Started: Aug 17, 2026

Contact the study team

• Clinical Trials · Phone: 001 888 493 8148

Official record on ClinicalTrials.gov — NCT07798505

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.